Stellate Ganglion Block for Stress Disorders, Traumatic
This study is evaluating whether a procedure called stellate ganglion block (SGB) might improve outcomes for people with PTSD.
See full descriptionAbout the trial for Stress Disorders, Traumatic
Treatment Groups
This trial involves 2 different treatments. Stellate Ganglion Block is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Stellate Ganglion Block will improve 1 primary outcome and 4 secondary outcomes in patients with Stress Disorders, Traumatic. Measurement will happen over the course of Screening, Week 0, Week 1, Week 2, Week 4, Week 8, Week 12, Week 13, Week 14, Week 16, Week 20, Week 24, Week 52.
Who is running the study
Principal InvestigatorPatient Q & A Section
Have there been any new discoveries for treating disease?
This article has tried to summarize recent advances (from basic research to medical treatments) in the field of disease treatment. Some of the topics that have received particular attention are the discovery of mechanisms of disease pathogenesis, development of novel therapeutic approaches, and potential biomarkers for disease detection. Further work is needed to identify safer therapies and prevention strategies to reduce the burden of disease.
What are the latest developments in stellate ganglion block for therapeutic use?
SGB using a variety of local anesthetics has been used as a pain management strategy for more than 100 years. However, there was no clear understanding of any specific mechanisms of action or anatomical structures contributing to analgesia by SGB. Data from a recent study from recent studies provide evidence that blockade of TRPV1 receptors in the dorsal root ganglion contributes significantly to the intrinsic analgesic effect of SGB. As such, SGB is now considered a viable alternative to conventional regional anesthesia procedures.
What are the common side effects of stellate ganglion block?
The most common side effect was hypotension (2%), followed by nausea (1%) and dizziness (0.7%). There were no cases of anaphylaxis. Results from a recent clinical trial indicate that stellate ganglion block is very safe when performed as an outpatient procedure under strict supervision by an experienced doctor.
How many people get disease a year in the United States?
The incidence of most common diseases in the general US population is increasing; however, this trend does not seem to apply to specific age groups. The discrepancy between peak incidence and prevalence among older adults suggests that some other age group should be targeted.
How quickly does disease spread?
The median time from diagnosis to death was 4 months (interquartile range [IQR]: 1.7-8.4 mo; mean 3.1 mo). The mode of death was brain metastasis (79.5%), followed by death due to primary tumor (16.9%) and systemic progressive disease (3.6%). Twenty-seven percent of patients died within 1 yr from diagnosis. Patients' characteristics were associated with TTR, and these should be taken into account when evaluating efficacy and safety of therapeutic agents in clinical trials.
What are common treatments for disease?
There were no common treatments for a variety of conditions, but there were some treatments that showed promise for certain conditions. For example, some medications have shown promise for treating breast cancer. For each treatment option, you can find their latest clinical trials using Power.
What is the average age someone gets disease?
The average age when a person first develops a medical condition is different depending on the type of disease, with some conditions appearing earlier in life than others. This phenomenon is called 'ageing'. For example, most common types of cancer emerge later in life (over 60 years old) whilst lung cancer emerges earlier in life (30–40 years old). This is why screening for cancer is recommended every 2 years for those over 50, and every 3 years for those between 30 and 50. Screening for cancers is not recommended before the age of 40, unless there is a family history of the disease, because it does not change outcomes.
What is the survival rate for disease?
Findings from a recent study shows that there is no difference in the survival rates of diseases when comparing male and female patients. This suggests that women's health status may not have an effect on patient survival. More research should be conducted into this so that we can reduce public concern over the survival rate of women living with certain cancers.
Can disease be cured?
The concept of “cure” is a powerful motivator. Individuals may view their disease as incurable when they do not perceive any possibility of a cure. This is particularly true of diseases that are chronic and progressive such as cancer and diabetes. Although patients may remain optimistic about the potential for cure, they often believe that the likelihood of a cure is low. The low perceived likelihood of a cure leads to patients' engagement in less intensive care against illness. Patients who have lower perceived likelihoods of a cure tend to engage in less health care services and are more likely to focus on self-management.
Who should consider clinical trials for disease?
This review summarizes the current evidence base for clinical trials involving individuals with suspected or known disease. Clinicians must be aware that these trials do not always lead to more conclusive results than observational studies.